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Abstract
We systematically reviewed the effectiveness and safety of continuous subcutaneous insulin infusion (CSII)
with insulin analogs compared with multiple daily injections (MDI) in pregnant women with diabetes mellitus.
We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials through May 2013.
Studies comparing CSII with MDI in pregnant women with diabetes mellitus were included. Studies using
regular insulin CSII were excluded. We conducted meta-analyses where there were two or more comparable
studies based on the type of insulin used in the MDI arm. Seven cohort studies of pregnant women with type 1
diabetes reported improvement in hemoglobin A1c (HbA1c) in both groups. Meta-analysis showed no differ-
ence in maternal and fetal outcomes for CSII versus MDI. Results were similar when CSII was compared with
MDI with insulin analogs or regular insulin. Studies had moderate to high risk bias with incomplete descriptions
of study methodology, populations, treatments, follow up, and outcomes. We conclude that observational
studies reported similar improvements in HbA1c with CSII and MDI during pregnancy, but evidence was
insufficient to rule out possible important differences between CSII and MDI for maternal and fetal outcomes.
This highlights the need for future studies to examine the effectiveness and safety of CSII with insulin analogs
and MDI in pregnant women with diabetes mellitus.
Introduction
In pregnant women with preexisting type 1 or type 2diabetes, poor glycemic control is associated with poor
pregnancy outcomes. Hyperglycemia at conception and in
early pregnancy is associated with congenital anomalies.1
Hyperglycemia later in pregnancy is associated with fetal
macrosomia, which can result in dysfunctional labor, cesarean
delivery, birth injury, stillbirth, shoulder dystocia and neonatal
hypoglycemia.2,3 In an effort to avoid these complications,
physicians recommend tight glycemic control prior to con-
ception and especially during pregnancy. A continuing chal-
lenge for perinatal providers is achieving tight glycemic
control in patients with type 1 and type 2 diabetes without
increasing the risk of maternal hypoglycemia.
To achieve tight glycemic control, physicians have tra-
ditionally used multiple daily injections of insulin (MDI) or
continuous subcutaneous insulin infusion (CSII) with reg-
ular insulin. Rather than checking hemoglobin A1c (HbA1c)
every 3 months, self-monitored fasting and 1-hour or 2-hour
post-prandial glucose levels Are assessed daily by the pa-
tient and reviewed weekly by their physicians to ensure
timely therapeutic changes to maintain tight control in
pregnant women.4 The American Association of Clinical
Endocrinologists recommends CSII for women with pre-
existing type 1 diabetes who are pregnant or considering
pregnancy;5 however, it is unclear if these insulin delivery
and glucose monitoring methods have any advantage over
MDI and self-monitoring of blood glucose, respectively.
One systematic review (n = 5 trials; 154 pregnancies)
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comparing CSII with MDI in pregnant women with pre-
existing type 1 or type 2 diabetes found little evidence to
support the use of one particular form of insulin delivery
over another.6 While a prior systematic review found no
substantial differences in short-term outcomes with CSII
versus MDI, there were still gaps in knowledge about some
fetal and maternal outcomes. An updated review was nec-
essary to determine whether the addition of newly published
studies would better inform the assessment of harms for
both the mother and developing fetus. It was important to
determine whether recent studies included long-term ma-
ternal outcomes or fetal outcomes such as growth in infants
up to 1 year. Maternal outcomes of diabetes management in
the reproductive years may have important implications for
a woman’s health later in her life course.
Because of the constant challenge of achieving glucose
control in pregnancies complicated by preexisting diabetes,
there is growing interest in the use of insulin analogues
among pregnant women with type 1 or type 2 diabetes. In
contrast to no-pregnant adults, the use of insulin analogs
during pregnancy represents a sharp departure from the
standard management of pregnancies complicated by type 1
diabetes. To date, however, the comparative benefits and
harms of MDI and CSII with insulin analogues in pregnancy
are largely unknown. Furthermore, the United States Food
and Drug Administration approved insulin Levemir in
pregnancy as a basal insulin analogue, supporting the im-
portance of studying the effects of MDI and CSII with insulin
analogues in pregnancy.7 It is important for perinatal clini-
cians to not only be aware of differences (e.g., glycemic
control) in the effectiveness of CSII using insulin analogues
and MDI, but to also understand the potential adverse effects
for both mother and fetus.
Our objectives in this paper are to systematically review
the differences in benefits and harms of MDI versus CSII with
insulin analogues on short term and long term (up to 1 year)
maternal and fetal outcomes in pregnant women with pre-
existing diabetes.
Methods
Data sources and searches
We conducted this review as part of a larger project sup-
ported by the Agency for Healthcare Research and Quality
(AHRQ); details of the methods can be found in the full
report8,9 or in the protocol, which was published at effecti-
vehealthcare.ahrq.gov. For the larger project, we initially
searched for original studies in Medline, Embase, and the
Cochrane Central Register of Controlled Trials in July 2011.
Our search string included medical subject headings and text
terms related to diabetes mellitus and insulin delivery, and
was not limited by language. In May 2013, we searched the
three databases again, this time using medical subject head-
ings and text terms focused on finding studies of pregnant
women with preexisting diabetes mellitus (see Appendix
Table A1). We also searched the reference lists of included
articles and relevant systematic reviews.
Data synthesis and analysis
Two authors independently reviewed citations for eligible
studies. We included studies of pregnant women with pre-
existing diabetes mellitus. We included studies that compared
CSII with MDI (defined as at least three injections per day). We
included studies that used insulin analogues in the CSII arm,
and long- and rapid-acting analogues and/or neutral protamine
Hagedorn (NPH) and regular insulin or insulin analogue in the
MDI arms because these insulin types are used in clinical
practice. In our primary review we have excluded studies in
which regular insulin was used in the CSII group because this is
not the preferred clinical practice.10,11 To be consistent with
that we excluded studies that used regular insulin in the CSII
arm in this population.10,11 Analogue insulin is found to be safe
and is recommended for pregnant women with diabetes mel-
litus.3,4 We searched for randomized controlled trials (RCTs)
and observational studies with a concurrent comparison group
that evaluated maternal and neonatal outcomes.
Maternal outcomes included intermediate outcomes
(HbA1c, hyperglycemia, weight gain, and hypoglycemia
frequency); severe hypoglycemia; cesarean delivery rates;
quality of life; microvascular disease (retinopathy, nephrop-
athy, and neuropathy); ketoacidosis; mortality; and process
measures (ratio of basal to bolus insulin, frequency of ad-
justing insulin therapy, adherence to insulin therapy, and
frequency of professional or allied health visits). Process
measures are important, as they may impact how the insulin
delivery and glucose monitoring methods affect the clinical
outcomes.
Neonatal outcomes included gestational age, birth weight,
neonatal hypoglycemia, major and minor anomalies, admis-
sion to a neonatal intensive care unit, stillbirth, neonatal
mortality, and perinatal mortality. We excluded studies that
were conducted in an inpatient setting or if the patients used
the treatment device for less than 24 hours. Conflicts re-
garding article inclusion were resolved through consensus
adjudication.
Using standardized data extractions forms, one reviewer
extracted information on study characteristics (e.g., design,
study period, follow up); study participants (e.g., age, gender,
race, baseline HbA1c, weight, type of diabetes, and duration
of diabetes); eligibility criteria; interventions [device model,
type of insulin, MDI schedule, length of technology use,
changes in insulin type used, patients/staff training, timing of
treatment initiation in relation to pregnancy (prenatal, first
trimester, second trimester), adherence to wearing the de-
vice]; definitions; and outcome measures, including mea-
sures of variability. A second reviewer checked abstracted
data for completeness and accuracy.
Two reviewers independently assessed study quality. The
quality assessment of observational studies was based on the
Downs and Black quality checklist.12 We conducted separate
meta-analyses when possible based on the type of insulin
used in the MDI arm. It was done when there were at least two
studies that were fairly comparable with respect to study de-
sign, population characteristics, and study duration. For con-
tinuous outcomes, we calculated a weighted mean difference
in change scores between groups using a random-effects
model, and for dichotomous outcomes, using a combined
relative risk using the DerSimonian and Laird method.13
Heterogeneity among trials was tested using a chi-squared test
(a £ 0.10) or an I2 statistic ( > 50%).14 Meta-analyses were
conducted using STATA (Intercooled, version 9.2, StataCorp,
College Station, TX). We qualitatively summarized studies
that were not amenable to pooling.
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We graded the strength of the evidence by adapting a
scheme recommended in the Methods Guide for Effective-
ness and Comparative Effectiveness Reviews.15 We graded
the evidence for each treatment comparison for each out-
come. We assessed the strength of evidence by assessing risk
of bias, consistency, directness, precision, publication bias,
and the magnitude of the effect.
Results
We retrieved 7,118 unique records from the original and
updated searches.8 We reviewed 753 articles for inclusion
(see Fig. 1). Of these, seven observational studies addressed
the study questions among pregnant women, and all evalu-
ated CSII versus MDI therapy in pregnant women with pre-
existing type 1 diabetes. One was a prospective study16 and
six were retrospective cohort studies.17–22 We did not iden-
tify any studies conducted primarily among pregnant women
with preexisting type 2 diabetes, and none of the studies in
pregnant women were randomized clinical trials.
None of the studies evaluated maternal mortality, micro-
vascular disease, quality of life, process measures, or birth
trauma.
Qualitative summary
One study enrolled patients from an outpatient clinic,18
two studies enrolled from diabetes ob-gyn/pregnancy clin-
ics,16,20 and another study enrolled patients from a university
clinic (see Table 1).17 One study did not report where patients
were enrolled.19 One study specifically stated that patients
were managed by a team including endocrinologists and
obstetricians/gynecologists.17 Studies were conducted in
Italy,18,19 India,21 Poland,17,22 United Kingdom,16 and
Spain.20 Women were given the choice to select either MDI
or CSII in one study.16 Studies did not report relevant details
of study design uniformly.
The number of participants per arm ranged from 14 to 86
pregnant women.16–22 Three studies reported having 100%
Caucasian women.17,18,22 Women entered the studies at
various stages of pregnancy. All study participants had pre-
existing type 1 diabetes, except that one study reported that
one of the 17 pregnant women in the CSII arm had pre-
existing type 2 diabetes, and one of the 23 women in the MDI
arm had type 2 diabetes.16 Two studies reported that CSII was
started 6 months before participants became pregnant.18,19
One study reported enrolling participants 3 or 6 months be-
fore conception,21 and another reported enrolling them dur-
ing first trimester.22 One study reported enrolling some of the
study participants on CSII before pregnancy.17
The mean age of study populations ranged from 26 to
31.34 years. The mean HbA1c during the first trimester ran-
ged from 6.9% to 7.8%,16–22 and the mean body mass index,
reported in seven studies, ranged from 21.8 to 26.19 kg/m2.
Baseline body mass index did not differ by arm.17–19 The
duration of diabetes was reported in five studies and ranged
from 7.7 to 16.5 years.17–19,21 One study reported that
FIG. 1. Summary of the
literature search. *Total may
exceed number in corre-
sponding box, as articles
could be excluded for more
than one reason at this level.
{Data from 35 studies in 38
publications: 28 compared
MDI with CSII (9 in children
and adolescents with type 1
diabetes; 9 in adults with
type 1 diabetes; 4 [5 publi-
cations] in adults with type 2
diabetes); 9 (10 publications)
compared rt-CGM with
SMBG; 4 (5 publications)
compared a sensor-aug-
mented pump with MDI/
SMBG. CENTRAL, Central
Register of Controlled Trials;
CSII, continuous subcutane-
ous insulin infusion; hrs,











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































diabetes was diagnosed at the age of 14 years for both
groups.22 Studies did not report on withdrawals. Insulin
treatments varied across studies. Five studies reported that
insulin lispro was used primarily for the CSII arm,16,17,19,20,22
and the type of insulin was not specified in the CSII arm in
one study.18 We tried to contact the authors to confirm the
type of insulin used in the CSII arm, but we did not receive a
response. Since insulin analogs were used in the MDI arm, we
assumed that insulin analogs were used in the CSII arm as
well. One study reported using either Lispro or Aspart in the
CSII arm.21
In the MDI groups, NPH insulin was used in four stud-
ies17,18,20,22 and insulin glargine was used in two other
studies.16,19 One study reported using rapid acting insulin
analog in the MDI arm.21 Two studies reported using four or
more insulin injections daily in the MDI arms.16,18 One study
had a total of four arms, MDI and CSII arms using regular
insulin and MDI and CSII arms using insulin lispro. We in-
cluded the lispro-based arms for our analyses to be consistent
with other included studies.20 Four studies reported on the
provision of training prior to initiating insulin pump therapy
in the CSII arms.16,18,20,22 The mean duration of therapy was
reported in three studies and ranged from 36 to 40 weeks.16–18
Reported glycemic targets varied across studies. One study
specified a HbA1c target of 6.5%,
16 one a preprandial blood
glucose target of 4.99 mmol/L (90 mg/dL) and a postprandial
blood glucose target of 7.2 mmol/L (130 mg/dL),18 and an-
other a preprandial blood glucose target of 3.3 to 4.99 mmol/
L (59.4 to 90 mg/dL).17 One study reported a fasting blood
sugar target of 5 mmol/L (90.1 mg/dL) and 2 hours post-
prandial target of 6.7 mmol/L (120.7 mg/dL).22 Only one
study reported on guidelines for management of blood glu-
cose between visits.16
Maternal outcomes
HbA1c. All seven studies reported an improvement in
HbA1c in both the CSII and MDI groups during pregnancy
without any significant difference between groups in HbA1c or
substantial differences across the three trimesters of pregnancy
(see Table 2). The mean between-group differences in
third trimester HBA1C values in each of the studies were 0.2
(95% confidence interval [95% CI], - 0.3 to 0.7),18 0.6 (95%
CI, - 0.7 to 1.9),16 - 0.3 (95% CI, - 0.6 to - 0.03),19 - 0.4
(95% CI, - 0.8 to 0.04),17 and 0.4 (95% CI, - 0.9 to 1.7).20
One study reported a significant (p < 0.05) reduction In HBA1C
level compared with baseline in each trimester in both groups.
There was statistically insignificant but higher reduction in
HBA1C in the CSII treated group in all three trimesters com-
pared with the MDI treated group.21 Another study reported a
significant reduction in HBA1C level during pregnancy in the
CSII group compared with the MDI group, particularly in
women with the highest HBA1C concentrations in the first
trimester.22 We did not perform a meta-analysis, because only
two studies reported baseline mean HbA1c. One was a retro-
spective study and the other was a prospective study.16,19
Cesarean delivery. Six studies reported on the rate of
cesarean delivery but did not distinguish between elective,
repeat, or other causes for cesarean delivery (see Table 3).17–22
One study found a higher rate of cesarean delivery in women in
the CSII arm compared with women in the MDI arm, but the
study did not provide data on further analysis.20 One study
reported a very high rate of cesarean delivery in both com-
parison groups: 71% in CSII group and 62% in MDI group.22
Meta-analysis of the three retrospective studies comparing
CSII with MDI found that used insulin analogues in the MDI
arm showed a combined relative risk of 1.01 (95% CI, 0.9 0 to
1.14; see Fig. 2a).18,19,21 We found no evidence of statistical
heterogeneity (I2 of 0%). Meta-analysis of three studies that
allowed regular insulin to be used in the MDI arm did not
change the results, although statistical heterogeneity was high
(I2 = 58.1%).
Maternal hypoglycemia. Four studies compared the
number of severe hypoglycemic events in women using CSII
versus MDI.17–20 Another study reported the following about
severe hypoglycemia: ‘‘Indeed, the number of severe hypo-
glycemic episodes decreased significantly in CSII patients
during pregnancy, although minimal glucose values were
similar in both groups.’’ The study did not report actual
numbers, so this study was not included in the meta-analysis.22
A meta-analysis of two retrospective cohort studies that used
Table 2. Differences in HbA1c by Trimester in the CSII and MDI Arms in Women












Volpe et al., 201018 MDI, 22 7.4 – 6.1 NS
CSII, 20 6.9 – 6.3
Cypryk et al., 200817 MDI, 86 7.8 6.7 6.8 NS
CSII, 30 7.4 6.5 6.4
Kernaghan et al., 200816 MDI, 18 7.3 6.6 6.44 NS
CSII, 24 6.95 6.3 6.63
Bruttomesso et al., 201119 MDI, 44 7.2 6.7 6.5 NS
CSII, 100 6.6 6.1 6.2
Chico et al., 201120 MDI, 16 6.1 5.8 5.9 NS
CSII, 59 6.3 6.0 6.3
Talaviya et al., 201321 MDI, 20 7.8 7.5 7.2 NS
CSII, 14 7.8 7.2 6.7
Wender-Ozegowska et al., 201322 MDI, 64 7.1 6.2 6.3 NS
CSII, 64 7.5 6.6 6.3
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insulin analog in the MDI arm showed no difference in the
rate of maternal hypoglycemia for CSII compared with
MDI: combined relative risk of 0.77 (95% CI, 0.18 to 3.34;
see Fig. 2b).18,19 We found no evidence of statistical het-
erogeneity, and no single study influenced the results. In-
cluding studies that allowed regular insulin to be used in the
MDI arm did not change the results.
Maternal weight gain. Three studies measured weight
gain in pregnant women with preexisting diabetes treated
with MDI and CSII.18,20,22 The difference in weight gain
between the CSII and MDI treatment arms was not statisti-
cally significant in these studies.18,20
Ketoacidosis. One study reported diabetic ketoacidosis
in pregnant women with preexisting diabetes treated with
MDI and CSII.19 This study reported that there were two
episodes (4.7%) in the MDI arm and one episode (1.1%) in
the CSII arm.19
Neonatal outcomes
Gestational age at delivery. Six studies reported on
gestational age at delivery and found no significant difference
between the MDI and CSII groups. Gestational age at de-
livery ranged from 36.3 weeks to 38 weeks in the MDI arms
and 36.3 weeks to 38 weeks in the CSII arms.16–19,21,22
Neonatal hypoglycemia. Six studies reported rates of
neonatal hypoglycemia.17–22 This was defined as a blood
glucose less than 2.2 mmol/L (or less than 40 mg/dL) in four
studies17,19,20,22 and was not defined in two studies.18,21
Meta-analysis of three retrospective cohort studies that used
Table 3. Rates of Cesarean Section Between











Volpe et al., 201018 94% 95% NS











FIG. 2. Combined relative
risk of maternal outcomes in
MDI versus CSII interven-
tions among pregnant women
with preexisting type 1 dia-
betes. (a) Combined relative
risk of cesarean delivery in
MDI versus CSII interven-
tions among pregnant women
with preexisting type 1 dia-
betes. (b) Combined relative
risk of severe maternal hypo-
glycemia in MDI versus CSII
interventions among pregnant
women with preexisting type
1 diabetes. 95% CI, 95%
confidence interval; RR, rela-
tive risk.
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only insulin analogues in the MDI arm for frequency of
neonatal hypoglycemia showed a combined relative risk of
neonatal hypoglycemia for CSII compared with MDI of 0.97
(95% CI, 0.51 to 1.84; see Fig 3a).18,19,21 We found no evi-
dence of statistical heterogeneity, and no single study sig-
nificantly influenced results. Meta-analysis of three
retrospective cohort studies that allowed regular insulin in the
MDI arm showed a combined relative risk for neonatal hy-
poglycemia for CSII compared with MDI of 1.19 (95% CI,
0.65 to 2.17; see Fig. 3a).17,20,22
Birth weight. Five studies reported on mean birth weight,
which ranged from 3101 to 3767 grams (see Table 4).17–19,21,22
Meta-analysis of three retrospective cohort studies that used
only insulin analog in the MDI arm showed a combined mean
between-group difference in birth weight for CSII compared
with MDI of 91.52 g, but this difference was not statistically
significant (95% CI, - 73.28 to 256.31 g; see Fig. 3b).18,19,21
Meta-analysis of two retrospective cohort studies that al-
lowed regular insulin in the MDI arm showed a combined
mean between-group difference in birth weight for CSII
compared with MDI of - 24.80 g, but this difference was
not statistically significant (95% CI, - 245.58 to 195.99 g;
see Fig. 3b).17,22 We found no evidence of statistical het-
erogeneity, and no single study significantly influenced the
results.
Congenital anomalies. Three studies reported on major
congenital anomalies in pregnant women treated with CSII
versus MDI.18–20 Women initiated CSII therapy prior to
FIG. 3. Combined relative
risk of neonatal outcomes in
MDI versus CSII interven-
tions among pregnant women
with preexisting type 1 dia-
betes. (a) Combined relative
risk of neonatal hypoglyce-
mia comparing CSII with
MDI among pregnant women
with preexisting diabetes. (b)
Combined mean between-
group difference between
MDI and CSII in birth weight
among infants born to wo-
men with preexisting type 1
diabetes. (c) Combined rela-
tive risk of major congenital
anomalies in MDI versus
CSII interventions among
infants born to women with
preexisting type 1 diabetes.
(d). Combined relative risk
of neonatal intensive care
unit admission in MDI versus
CSII interventions among
infants born to women with
preexisting type 1 diabetes.
(e) Combined relative risk of
preterm delivery in MDI
versus CSII interventions
among pregnant women with
preexisting type 1 diabetes.
Figure 3 continued
/
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pregnancy in these studies.18–20 Major congenital anomalies
were defined as life-limiting, requiring surgery, or causing
significant functional or cosmetic impairment,20 or following
the European Registration of Congenital Anomalies and
Twins (EUROCAT) classification,19 or not further speci-
fied.18 Two studies reported on congenital anomalies. One
shows no evidence of any congenital anomaly in either
group,21 and the other reported four (6.2%) in CSII group and
two (3.1%) in MDII group.22 Both studies didn’t have a
definition for congenital anomalies.
We performed meta-analysis for two retrospective cohort
studies and it showed a combined relative risk of 2.12 favoring
MDI that was not significant (95% CI, 0.38 to 11.77, Fig.
3c).19,20 We did not find evidence of statistical heterogeneity.
Three studies reported on minor congenital anomalies.
None of the studies defined minor congenital anomalies.
There were no minor congenital anomalies in either group in
two studies,16,18 and the rate of minor congenital anomalies
were 2.3% (2/86 patients) in the MDI group and 13% (4/30
patients) in the CSII group in the other study ( p = 0.05).17
FIG. 3. (Continued).
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Neonatal intensive care unit admission. Two studies
reported on neonatal intensive care unit admissions
rates.18,19 These ranged from 9% to 35% in the MDI groups
and 5% to 33% in the CSII groups.18,19 Meta-analysis of
these two retrospective cohort studies comparing CSII
with MDI showed a combined relative risk of 0.84
(95% CI, 0.43 to 1.68; Fig. 3d).18,19 There was no evidence
of statistical heterogeneity, and no evidence of publica-
tion bias.
Preterm delivery. In the six studies reporting on preterm
delivery, the definition was not uniform. Preterm delivery
rates ranged from 7.7% to 40% in the MDI groups and 0% to
33% in the CSII groups (see Table 5).17–22 Meta-analysis of
the three retrospective studies comparing CSII with MDI
with insulin analogues showed a combined relative risk of
0.91 (95% CI, 0.59 to 1.39; see Fig. 3e).18,19,21 Meta-analysis
of the three retrospective studies comparing CSII with MDI
with regular insulin showed a combined relative risk of 1.21
(95% CI, 0.69 to 2.13; see Fig. 3e).17,20,22
Stillbirth rates and neonatal and perinatal mortality. Five
studies reported on stillbirth rates. Three reported no still-
births in either group,16,18,20 and one study reported having
one stillbirth in the MDI group.17 Another study reported
having two intrauterine deaths (after the 22 week) in each
group.22 Three studies reported on neonatal mortality rate.
One neonatal death occurred in both arms of one study,17 no
neonatal deaths in either group in another,16 and a 0%
neonatal mortality rate in the MDI group and 2.7% rate in
the CSII group in a third study.20 One study reported on
perinatal mortality rate. This study reported a 0% perinatal
mortality rate in the MDI group and 2.7% rate in the CSII
group.20
Summary
The strength of evidence examining the comparative
effectiveness of CSII versus MDI in women with pre-
existing type 1 diabetes was low for the outcome of HbA1c
and insufficient for the other outcomes, limiting our ability
to assess differences in outcomes for the two insulin de-
livery modalities (see Appendix Table A2). The strength of
evidence was considered low because the evidence was
limited to observational studies. There were no RCTs that
met our eligibility criteria. Also, for the outcomes exam-




Our systematic review of observational studies showed no
difference in HbA1c lowering between CSII and MDI treat-
ment in pregnant women with type 1 diabetes. However, the
strength of this evidence was low due to the risk of bias and
lack of precision in outcome estimates. The evidence was
insufficient to draw definitive conclusions about other ma-
ternal and fetal outcomes for pregnant women with type 1
diabetes. Results were similar when CSII was compared with
MDI with insulin analogs or regular insulin.
A prior systematic review and meta-analysis of six ran-
domized clinical trials comparing CSII using regular insulin
and MDI in pregnant diabetic women also showed that
pregnancy outcomes and glycemic control were not sig-
nificantly different among these two groups. While the CSII
group had a higher number of ketoacidosis episodes and
diabetic retinopathy, the difference was not statistically
significant. These findings were similar to ours despite
differences in inclusion criteria (e.g., CSII using regular
insulin in the prior study). The authors concluded that it is
necessary to conduct large multicenter trials to examine
maternal and fetal outcomes.23 Effective glucose control in
pregnancies complicated by type 1 and type 2 diabetes has
important short-term and lifetime clinical implications for
the expectant mother and developing fetus. Treatment out-
comes during pregnancy are thought to offer a view of po-
tential complications across the life course for mother and
child.24 This life course model provides a framework in
which to view the comparative effectiveness and safety of
newer methods for insulin delivery and glucose control (i.e.,
CSII) compared with traditional insulin delivery methods. It
is well established that tight glucose control during preg-
nancy reduces the short-term risk of adverse delivery out-
comes, such as macrosomia, fetal growth restriction and
cesarean delivery.
There is also an emerging chain of data indicating that the
intrauterine hormonal milieu in diabetic pregnancies can in-
fluence fetal development and programming, altering fetal
metabolism and increasing the risk of chronic disease in the
offspring.25 Efforts that compare the effectiveness of insulin
delivery in pregnancies complicated by type 1 and especially
type 2 diabetes provide important data that can be directly
translated into clinical care. Also, such data can inform
Table 4. Neonatal Birth Weights in the CSII
and MDI Arms in Women






Volpe et al., 201018 3101 3295 Not reported








Table 5. Rates of Preterm Delivery Between
MDI and CSII Arms in Women









Volpe et al., 201018 40 33 NS




Chico et al., 201120 7.7 13.5 NA
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guidelines for future perinatal care services and improve the
current paradigm of perinatal practice.
Strengths and limitations
Most of the observational studies included in this review
had important limitations.16–21 All studies provided limited
descriptions of study setting, study population, treatment,
follow up and outcomes. One study did not report type of
insulin used in the CSII arm (although in that study insulin
analog had been used in the MDI arm), and none of the
studies described details of losses to follow-up. Most studies
did not report the racial and ethnic composition of the study
populations. For those that did provide this information, the
majority of participants were Caucasian, likely reflecting the
fact that type 1 diabetes is much rarer in minority popula-
tions. Since no studies focused on pregnant women with
preexisting type 2 diabetes, we were unable to draw con-
clusions about the effectiveness of insulin delivery methods
in this population. Studies used heterogeneous definitions of
hypoglycemia, hyperglycemia, and weight gain, preventing
us from combining data to determine effect estimates for
some of these intermediate outcomes. None of the studies
included data on long-term macrovascular complications of
diabetes. This is likely related to the fact that these compli-
cations develop over many years, and studies generally only
followed subjects during pregnancy.
Several limitations of our systematic review deserve men-
tion. First, systematic reviews are limited by the state of the
available literature. Notably, our evidence synthesis is based
on observational studies and not RCTs. Thus, our findings are
particularly susceptible to confounding and selection bias.
Second, the applicability or generalizability of any systematic
review is constrained by the criteria used to select studies for
inclusion. Third, unlike previous reviews on this topic we have
excluded studies that used regular insulin in the CSII arm from
our meta-analysis, leaving us with only a limited number of
studies with small sample size for each outcome. Finally, while
our search strategy was comprehensive and included non-
English language publications, we may have missed studies
that have not yet been reported in a peer-reviewed journal.
Finally, our study did not address the availability, costs and
insurance coverage of CSII, which may be obstacles to their
use. In general, insulin pumps cost between $6,000 and $7,000,
with supply costs of approximately $2,000 per year (Med-
tronic, Animas, and OmniPod Personal communications). The
extent to which insurance covers these costs will contribute to
their use in practice.
Interpretation
From this systematic review of observation studies we
found that CSII and MDI do not affect HbA1c differentially in
pregnant women with preexisting type 1 diabetes with low
strength of evidence.
Conclusions
Our report highlights that the systematic review of avail-
able observational studies may not facilitate making clinical
decision to choose CSII or MDI for pregnant women with
preexisting type 1 diabetes. This report also shows the need
for several areas of future research examining the effect of
insulin delivery in the management of preexisting diabetes
mellitus in pregnant women. We identified a need for well-
conducted RCTs of intensive insulin therapy delivered via
CSII versus MDI in pregnant women with both type 1 and
type 2 diabetes. In addition to HbA1c, other important out-
comes to examine include maternal outcomes (cesarean de-
livery, hypoglycemia, weight gain, quality of life, and
mortality) and neonatal outcomes (gestational age at deliv-
ery, hypoglycemia, birth weight, congenital anomalies,
neonatal intensive care unit admission, preterm delivery,
stillbirths, neonatal and perinatal mortality, and birth trau-
ma). Also, to allow cross-comparisons, future RCTs and
observational studies should use a uniform definition of hy-
poglycemia, preferably that recommended by the American
Diabetes Association.26 Finally, cost-effectiveness of CSII
versus MDI should be examined in future research studies.
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Appendix
Table A2. Limitations on the Evidence of the Comparative Effectiveness of MDI









Precise Consistent 6 (All
OBS)/0
Meta-analysis of three retrospective cohort studies
comparing CSII with MDI that used insulin analogues
in the MDI arm showed a combined relative risk
of 1.01 (95% CI, 0.90 to1.14; see Fig. 2a).18,19,21
Including studies that allowed regular insulin to be
used in the MDI arm did not change the results.
Maternal
hypoglycemia
Imprecise Consistent 4 (All
OBS)/0
Meta-analysis of two retrospective cohort studies
showed no difference in the rate of maternal
hypoglycemia for CSII compared with MDI:
combined relative risk of 0.77 (95% CI, 0.18
to 3.34).18,19 Including studies that allowed regular









There was no difference in weight gain between the
CSII and MDI intervention groups in all three
reported studies. The mean between-group difference
in weight gain was 1.9 kg (95% CI, - 0.9 to 4.7 kg)
in one study.18 The other study reported a median
weight gain of 13.5 kg in the CSII group and
13.9 kg in the MDI group.20
Ketoacidosis Imprecise Unknown 1 (All
OBS)/0
One study reported that there were two episodes
of ketoacidosis (4.7%) in the MDI arm and one
episode (1.1%) in the CSII arm.19
Other maternal
outcomes
NA NA 0/0 We did not include any studies that evaluated maternal
mortality, microvascular or macrovascular disease,







Gestational age at delivery ranged from 36.3 weeks
to 38 weeks for MDI and from 36.3 weeks to
38 weeks for CSII, and there was no significant
difference between the MDI and CSII groups.16–19,21,22
(continued)




((‘‘Diabetes Mellitus’’[mh] OR Diabet*[tiab] OR hyperglycem*[tiab] OR
hyperglycaem*[tiab]) AND (‘‘Insulin Infusion Systems’’[mh] OR ‘‘continuous
subcutaneous insulin’’[tiab] OR CSII[tiab] OR ‘‘insulin pump’’[tiab] OR ‘‘insulin
pumps’’[tiab] OR ‘‘pump therapy’’[tiab] OR ‘‘pump treatment’’[tiab] OR
‘‘artificial pancreas’’[tiab] OR (‘‘Monitoring, Ambulatory’’[mh] AND (glucose[tiab]
OR insulin[tiab] OR glycem*[tiab] OR glycaem*[tiab])) OR ‘‘CGM’’[tiab] OR
(‘‘continuous glucose’’[tiab] AND (monitor*[tiab] OR sensing[tiab] OR





((‘‘Diabetes Mellitus’’[mh] OR Diabet*[tiab] OR hyperglycem*[tiab] OR
hyperglycaem*[tiab]) AND (‘‘Insulin Infusion Systems’’[mh] OR ‘‘continuous
subcutaneous insulin’’[tiab] OR CSII[tiab] OR ‘‘insulin pump’’[tiab] OR
‘‘insulin pumps’’[tiab] OR ‘‘pump therapy’’[tiab] OR ‘‘pump treatment’’[tiab]
OR ‘‘artificial pancreas’’[tiab] OR (‘‘Monitoring, Ambulatory’’[mh] AND (glucose[tiab]
OR insulin[tiab] OR glycem*[tiab] OR glycaem*[tiab])) OR ‘‘CGM’’[tiab] OR
(‘‘continuous glucose’’[tiab] AND (monitor*[tiab] OR sensing[tiab] OR sensor*[tiab])))
AND (pregnancy[mh] OR pregnan*[tiab])) NOT (animal[mh] NOT human [mh])






quality studies Main findings
Neonatal
hypoglycemia
Imprecise Consistent 6 (All
OBS)/0
Meta-analysis of three retrospective cohort studies
that used only insulin analogues in the MDI arm for
frequency of neonatal hypoglycemia showed a
combined relative risk of neonatal hypoglycemia for
CSII compared with MDI of 0.97 (95% CI, 0.51 to 1.84;
see Fig. 3a).18,19,21 Meta-analysis of three retrospective
cohort studies that allowed regular insulin in the MDI
arm showed a combined relative risk for neonatal
hypoglycemia for CSII compared with MDI of 1.19





Meta-analysis of three retrospective cohort studies
that used only insulin analog in the MDI arm showed
a combined mean between-group difference in birth
weight for CSII compared with MDI of 91.52 g,
but this difference was not statistically significant
(95% CI, - 73.28 to 256.31 g; see Fig. 3b).18,19,21
Meta-analysis of two retrospective cohort studies
that allowed regular insulin in the MDI arm showed
a combined mean between-group difference in birth
weight for CSII compared with MDI of - 24.80g,
but this difference was not statistically significant




Imprecise Unknown 2 (All
OBS)/0
Meta-analysis for only two retrospective cohort studies
for major congenital anomalies showed a pooled RR
of 2.12 favoring MDI that was not significant








Three studies found no difference in minor congenital
anomalies between the MDI and CSII groups.
There were no minor congenital anomalies in either
group in two studies,16,18 and rates of minor
congenital anomalies and pregnancy termination
rates were 2.3% (2/86 patients) in the MDI group
and 13% (4/30 patients) in the CSII group ( p = 0.05).17
NICU
admissions
Imprecise Unknown 2 (All
OBS)/0
Meta-analysis on two retrospective cohort studies
for admission to the neonatal intensive care unit
showed a pooled RR of 0.84 that was not significant
(95% CI, 0.43 to 1.68).18,19
Preterm
delivery
Imprecise Unknown 6 (All
OBS)/0
Meta-analysis of the three retrospective studies
comparing CSII with MDI with insulin analogues
showed a combined relative risk of 0.91 (95% CI,
0.59 to 1.39; see Fig. 3e).18,19,21 Meta-analysis of the
three retrospective studies comparing CSII with MDI
with regular insulin showed a combined relative risk







Four studies reported on still birth rates. Three reported
that there were no still births in either group,16,18,20








Three studies reported on neonatal mortality rate.
Each group had one neonatal death in one study,17
no neonatal deaths in either group in another,16 and
a 0% neonatal mortality rate in the MDI group and







One study reported a 0% perinatal mortality rate
in MDI group and a 2.7% rate in CSII group.20
Birth trauma NA NA 0 We did not include any studies that reported
on birth trauma.
CI, confidence interval; CSII, continuous subcutaneous insulin infusions; g, grams; HbA1c, hemoglobin A1c; kg, kilograms; MDI,
multiple daily injections; NICU, neonatal intensive care unit; OBS, observational study; QOL, quality of life; RR, relative risk.
The strength of the evidence was defined as follows: High, high confidence that the evidence reflects the true effect. Further research is
unlikely to change our confidence in the estimate of the effect. Moderate, moderate confidence that the evidence reflects the true effect.
Further research may change our confidence in the estimate of the effect and may change the estimate. Low, low confidence that the
evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the
estimate. Insufficient, evidence is unavailable.
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